Format

Send to

Choose Destination
Fundam Clin Pharmacol. 2018 Oct;32(5):462-484. doi: 10.1111/fcp.12373. Epub 2018 Jul 2.

Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review.

Author information

1
Laboratoire de Biologie Médicale, Centre Hospitalier Léon-Jean Grégory, avenue du Roussillon, 66330, Thuir, France.
2
Clinical Pharmacology Department, Nantes University Hospital, institut de biologie, 9 quai Moncousu, 44093, Nantes Cedex 1, France.
3
EA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Nantes University Hospital, Nantes, France.
4
EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, Nantes University Hospital, Nantes, France.

Abstract

Cannabis is a plant that has been used for centuries to relieve a wide range of symptoms. Since the 1960s, interest in medical research into this plant has grown steadily. Already very popular for recreational use, a growing number of consumers not accustomed to using cannabis for psychoactive purposes have begun to use it as an alternative or complement to mainstream pharmaceutical medicines. The principal unsubstantiated or 'social' uses of cannabis are based mainly on data that is at best controversial, but usually not scientifically proven. The aim of this review was to identify the scientific basis and reasons that lead patients with cancer to consume cannabis, and also to identify whether there is a risk of interaction between cannabis and anticancer medicines through drug transporters (P-glycoprotein and other ATP-binding cassette superfamily members) Cytochromes P450 (3A, 1A, 2B, 2C, 2D families…) and glucuronyl transferases.

KEYWORDS:

anticancer drugs; cannabidiol; cannabinol; cannabis; herbal-drug interaction; tetrahydrocannabinol

PMID:
29660159
DOI:
10.1111/fcp.12373

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center